TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Starpharma Holdings Limited ( (AU:SPL) ) has issued an announcement.
Radiopharm Theranostics has entered into a research and option agreement with Starpharma to develop a novel radiopharmaceutical molecule using Starpharma’s DEP® platform. This collaboration marks a significant milestone for both companies, potentially enhancing Radiopharm’s cancer treatment offerings and demonstrating the applicability of Starpharma’s technology in targeted cancer therapies. The agreement includes an exclusive option for Radiopharm to license the developed asset, with significant financial terms tied to successful development and commercialization.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology, which is used to improve health outcomes for patients with serious illnesses like cancer. Their portfolio includes clinical-stage DEP® assets, preclinical radiopharmaceutical assets, and over-the-counter products. Radiopharm Theranostics is a clinical-stage company developing radiopharmaceutical products for cancer diagnostics and therapeutics, with a focus on areas of high unmet medical need.
Average Trading Volume: 805,090
Technical Sentiment Signal: Hold
Current Market Cap: A$92.01M
See more insights into SPL stock on TipRanks’ Stock Analysis page.